Front Page News
Cure SMA Receives Generous Donations from Fighting for Kaiden Foundation
Cure SMA would like to thank the Fighting for Kaiden Foundation for their generous donations to our equipment pool and research programs. The foundation’s generosity […]
Read More ›Record Number of Abstracts Submitted for the 2017 SMA Researcher Meeting
Abstract submission is now closed for the 2017 SMA Researcher Meeting. We are excited to announce that we received 125 submissions, a record number. Our […]
Read More ›Cytokinetics Announces Start of Second Cohort in Phase 2 Clinical Trial of CK-2127107 in Patients with SMA
Cytokinetics, Inc. today announced that the second cohort of the Phase 2 clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA), is open […]
Read More ›Cure SMA Coverage and Payment Policy Project Continues to Move Forward
The Cure SMA Coverage and Payment Policy Project has two distinct but complementary tracks: Outreach on behalf of our community. We’re working with public and […]
Read More ›Genentech Roche Releases Community Letter with Clinical Trial Updates
Genentech Roche provided the following community statement with clinical trial updates for SUNFISH (Type 2/3), FIREFISH (Type 1) and JEWELFISH. Dear SMA community, At Genentech […]
Read More ›Cure SMA Releases Schedule for the 2017 Annual SMA Conference
Cure SMA has released the schedule for the 2017 Annual SMA Conference, to be held at Walt Disney World in Orlando, FL, June 29 – […]
Read More ›Cure SMA Awards $140,000 Grant to Joceyln C̫t̩, PhD, University of Ottawa
Cure SMA has awarded a $140,000 research grant to Joceyln Côté, PhD, at The University of Ottawa, for his project, “Investigating the mechanism by which […]
Read More ›American College of Obstetricians and Gynecologists Recommends Expanded SMA Carrier Screening
The American College of Obstetricians and Gynecologists has released updated guidance on carrier testing for genetic conditions. The updated guidance includes, for the first time, […]
Read More ›AveXis Reports Results from Phase 1 Trial of AVXS-101
AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported topline results from the […]
Read More ›Know Your Resources: How Congressional Caseworkers Can Help You Obtain Insurance Coverage for New Therapies
Your elected officials who represent you in Washington, D.C. have caseworkers in their regional and district offices in your communities. These caseworkers can help you […]
Read More ›